Zenas BioPharma presented new data on obexelimab at the 6th International Symposium on IgG4-Related Disease, highlighting sustained clinical activity in treating IgG4-RD. Phase 3 INDIGO open-label extension results showed a high probability of patients remaining flare-free after 12 months and significantly reduced glucocorticoid toxicity compared to placebo. Additionally, a vaccine sub-study demonstrated effective immune responses during a treatment-free window without disease flares. These findings support obexelimab's potential as a steroid-sparing therapy for long-term management of this chronic autoimmune disease.
Zenas BioPharma's new data presentation on obexelimab in IgG4-related disease provides context for readers following health sector developments. For readers following health sector stocks, here is Pluang's market snapshot as of Oct 12, 2026 17:11 WIB: of 128 priced health-sector US stocks tradable on Pluang, 58 rose and 42 fell today. Notable movers include BNGO (BioNano Genomics Inc) at USD 1.40 with a -2.44% change and a typical hold time of 50 days, ROIV (Roivant Sciences Ltd.) at USD 34.70 with a -2.09% change and a typical hold time of 3 days, and HRTX (Heron Therapeutics Inc) at USD 0.41 with a +2.07% change and a typical hold time of 36 days.
Harmony Biosciences announced that Peter Anastasiou will become President and CEO effective January 1, 2027, succeeding Jeffrey M. Dayno, who will retire at the end of 2026. Dayno will remain as a non-executive advisor through 2027 to support the com...
The St. Louis Blues and Gray Media announced a multi-year deal to broadcast 10 select Thursday games over-the-air on ABC 32 in St. Louis and 10 other markets during the 2026-27 NHL season. This expands access to Blues games for over 4.8 million house...
Fate Therapeutics has appointed Jamie Harrell as Senior Vice President of Market Development & Commercial Operations to spearhead the commercialization of its CAR T-cell therapies, including FT819 and FT839, targeting autoimmune diseases like lupus n...
Iridex Corporation announced a two-year clinical study demonstrating that MicroPulse transscleral laser therapy significantly reduces intraocular pressure (IOP) and medication use in patients with early to advanced glaucoma. The study, involving 84 e...
The European Commission has chosen Neo Performance Materials' Silmet 2.0 as one of 46 Strategic Projects under the EU's Critical Raw Materials Act, recognizing its importance in rare earth processing. Greenland Mines, a key shareholder in Neo, sees t...
